Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.